Don’t miss the latest developments in business and finance.

Glenmark Pharmaceuticals receives final approval for Chlorzoxazone Tablets

Image
Capital Market
Last Updated : May 27 2020 | 11:33 AM IST
Glenmark Pharmaceuticals has been granted final approval by the United States Food & Drug Administration (USFDA) for Chlorzoxazone Tablets USP, 375 mg and 750 mg. This marks Glenmark's first ANDA approval out of their new North American manufacturing facility based in Monroe, North Carolina.

According to IQVIATM, sales data for the 12 month period ending March 2020, the Chlorzoxazone Tablets, 375 mg and 750 mg market achieved annual sales of approximately $20.9 million.

Glenmark's current portfolio consists of 163 products authorized for distribution in the U.S. marketplace and 45 ANDA's pending approval with the U.S. FDA. In addition to these internal filings, Glenmark continues to identify and explore external development partnerships to supplement and accelerate the growth of its existing pipeline and portfolio.

Powered by Capital Market - Live News

Also Read

First Published: May 27 2020 | 9:52 AM IST

Next Story